Pancreatitis on Ozempic (semaglutide 0.5-2 mg): Incidence, Severity, and Realistic Expectations

How common is pancreatitis on Ozempic?

The Ozempic label supplies a rate from its own glycemic-control trials: acute pancreatitis confirmed by adjudication in 7 Ozempic-treated patients, or 0.3 cases per 100 patient-years, against 3 comparator-treated patients, or 0.2 cases per 100 patient-years [1]. The label's postmarketing list also includes acute and necrotizing pancreatitis, sometimes fatal, but voluntary reports cannot show how often it occurs [1].

Wider trial data do not show a clear excess across the class. A 2025 meta-analysis of 21 randomized trials covering 99,599 patients and eight GLP-1 receptor agonists found no difference in pancreatitis between treated patients and controls [2]. A 2025 review of real-world studies in type 2 diabetes and obesity populations reported no clear increase in severe events such as pancreatitis [3]. One meta-analysis of 4 trials in 3,613 people with obesity but without diabetes found serious adverse events were 1.6 times more likely on semaglutide, mostly gastrointestinal and hepatobiliary events such as acute pancreatitis and cholelithiasis [4].

Does the 0.5, 1 or 2 mg dose change the risk?

Ozempic is titrated upward in steps: 0.25 mg weekly for 4 weeks (a starting dose, not a maintenance dose), then 0.5 mg, with any increase to 1 mg and then 2 mg coming no sooner than 4 weeks on the current dose [1]. The label's pancreatitis figures are not broken down by dose, so they do not show whether risk differs among Ozempic's 0.5 mg, 1 mg and 2 mg maintenance doses.

The 40-week trial of 2 mg versus 1 mg in 959 patients with type 2 diabetes reported no new safety signals, and gastrointestinal reactions occurred in 34% on 2 mg versus 30.8% on 1 mg [1]. Those percentages describe gastrointestinal reactions overall, such as nausea, vomiting and diarrhea, not pancreatitis [1].

How serious is it when it happens?

Pancreatitis can be severe. Hemorrhagic, necrotizing and fatal cases have been observed in people treated with GLP-1 receptor agonists, including Ozempic [1].

It is a different category from the ordinary gastrointestinal reactions in the trial tables. In the pooled placebo-controlled Ozempic trials (mean 32.9 weeks), any gastrointestinal reaction occurred in 15.3% on placebo, 32.7% on 0.5 mg and 36.4% on 1 mg, and 0.4%, 3.1% and 3.8% respectively stopped treatment for gastrointestinal reasons [1]. Pancreatitis is the reaction the label pairs with a discontinuation instruction [1].

What symptoms does the label describe?

The label describes pancreatitis as persistent or severe abdominal pain, sometimes radiating to the back, with or without nausea or vomiting, and directs prescribers to observe patients carefully for that pattern after starting Ozempic [1].

That pattern differs from the usual early nausea. In the pooled placebo-controlled Ozempic trials, nausea occurred in 6.1% on placebo, 15.8% on 0.5 mg and 20.3% on 1 mg; vomiting in 2.3%, 5% and 9.2%; and diarrhea in 1.9%, 8.5% and 8.8%, with most reports occurring during dose escalation [1]. Persistent or severe abdominal pain is the symptom the pancreatitis warning is built around, and the label describes it separately from those reactions [1].

What does the label say to do?

If pancreatitis is suspected, the Ozempic label says to discontinue the drug and initiate appropriate management [1]. The warning does not set out a restart protocol or a monitoring schedule for after the event [1].

Gallbladder disease is a separate labeled risk

Acute gallbladder disease is its own warning in the Ozempic label, separate from the pancreatitis warning. The label says that if cholelithiasis or cholecystitis is suspected, gallbladder studies are indicated [1].